Leerink Swann set a $27.00 price target on Kura Oncology (NASDAQ:KURA) in a report issued on Saturday, TipRanks reports. The firm currently has a buy rating on the stock.
Several other equities research analysts also recently weighed in on the company. Oppenheimer restated a buy rating on shares of Kura Oncology in a report on Tuesday, March 19th. BidaskClub upgraded Kura Oncology from a sell rating to a hold rating in a report on Tuesday, May 7th. ValuEngine upgraded Kura Oncology from a hold rating to a buy rating in a report on Wednesday, March 27th. HC Wainwright set a $31.00 price target on Kura Oncology and gave the stock a buy rating in a report on Wednesday, May 8th. Finally, Citigroup upped their price target on Kura Oncology from $18.00 to $25.00 and gave the stock a buy rating in a report on Friday, May 24th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Kura Oncology presently has an average rating of Buy and a consensus target price of $28.00.
Shares of NASDAQ KURA opened at $19.48 on Friday. The business’s 50-day moving average is $16.55. The company has a current ratio of 13.80, a quick ratio of 13.80 and a debt-to-equity ratio of 0.05. Kura Oncology has a 1-year low of $10.20 and a 1-year high of $22.00. The stock has a market cap of $711.00 million, a P/E ratio of -11.33 and a beta of 2.44.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc increased its holdings in shares of Kura Oncology by 21.7% in the 4th quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock valued at $73,000 after acquiring an additional 923 shares during the last quarter. CWM LLC purchased a new position in shares of Kura Oncology in the 1st quarter valued at about $25,000. DekaBank Deutsche Girozentrale increased its holdings in shares of Kura Oncology by 22.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 12,000 shares of the company’s stock valued at $235,000 after acquiring an additional 2,200 shares during the last quarter. Legacy Advisors LLC purchased a new position in shares of Kura Oncology in the 1st quarter valued at about $65,000. Finally, Alps Advisors Inc. increased its holdings in shares of Kura Oncology by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 91,873 shares of the company’s stock valued at $1,524,000 after acquiring an additional 3,974 shares during the last quarter. Institutional investors and hedge funds own 83.93% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: Should you buy a closed-end mutual fund?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.